Cencora
COR
Market cap $57.3B

295.54 USD

+0.50

0.17%

At close Jun 13, 4:00 PM EDT

After hours

295.54

+0.00

0.00%

1 day

0.17%

5 days

3.09%

1 month

5.93%

3 months

15.44%

6 months

27.26%

Year to date

31.50%

1 year

27.26%

5 years

207.18%

10 years

167.14%

About: Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.

Employees: 46,000

Healthcare Medical Distribution

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

125% more funds holding in top 10

Funds holding in top 10: 12 [Q4 2024] → 27 (+15) [Q1 2025]

77% more first-time investments, than exits

New positions opened: 184 | Existing positions closed: 104

32% more call options, than puts

Call options by funds: $1.39B | Put options by funds: $1.05B

17% more capital invested

Capital invested by funds: $43.5B [Q4 2024] → $51B (+$7.5B) [Q1 2025]

4% more funds holding

Funds holding: 1,208 [Q4 2024] → 1,261 (+53) [Q1 2025]

8% less repeat investments, than reductions

Existing positions increased: 432 | Existing positions reduced: 471

5.55% less ownership

Funds ownership: 100.16% [Q4 2024] → 94.6% (-5.55%) [Q1 2025]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$285

4%

downside

Avg. target

$332

12%

upside

High target

$355

20%

upside

5 analyst ratings

4 positive

80%

1 neutral

20%

0 negative

0%

Wells Fargo Stephen Baxter	14%upside $337	Overweight Upgraded	3 Jun 2025
Citigroup Michael Rollins	20%upside $355	Buy Maintained	8 May 2025
Baird David Rodgers	18%upside $350	Outperform Maintained	8 May 2025
UBS Kevin Caliendo	13%upside $335	Buy Maintained	29 Apr 2025
B of A Securities Michael Funk	4%downside $285	Neutral Maintained	11 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about COR published over the past 30 days

Zacks Investment Research

Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?

Here is how Cencora (COR) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.

Is Cencora, Inc. (COR) Stock Outpacing Its Medical Peers This Year?

Zacks Investment Research

Here's Why You Should Add Cencora Stock to Your Portfolio Now

COR continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Here's Why You Should Add Cencora Stock to Your Portfolio Now

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. “Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value,” said Mark Du.

Cencora Elects Lori J. Ryerkerk to Its Board of Directors

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

Cencora gets a buy rating, agreeing with today's consensus from Wall St. The sector and macro environment points to continued demand for the healthcare supplies and niche specialty drugs Cencora can distribute. Future share price targets point to significant potential upside over 3 years, justifying a buy despite the stock trading above average now.

Cencora Continues To Deliver As A Healthcare Distributor With Further Growth Signs

Zacks Investment Research

Here's Why Cencora (COR) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Cencora (COR) is a Strong Momentum Stock

Zacks Investment Research

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Cencora, Inc. (COR) Hits Fresh High: Is There Still Room to Run?

Zacks Investment Research

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Cencora (COR) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks Investment Research

COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised

COR's second-quarter fiscal 2025 results showcase a strong segmental performance. The company's earnings guidance for fiscal 2025 looks encouraging.

COR Q2 Earnings & Revenues Beat Estimates, '25 EPS Guidance Raised

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora, Inc COR on Wednesday reported second-quarter 2025 sales increased 10.3% to $75.5 billion, missing the consensus of $75.68 billion, primarily due to an 11.4% increase in revenue within the U.S. Healthcare Solutions segment.

Cencora's Boosts Annual Forecast On Strong Demand For Weight Loss Drugs, Specialty Products Despite Mixed Q2 Earnings

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

Cencora, Inc. (NYSE:COR ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Bennett Murphy - Senior Vice President, Head of Investor Relations & Treasury Bob Mauch - President & Chief Executive Officer Jim Cleary - Executive Vice President & Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Capital Lisa Gill - JPMorgan George Hill - Deutsche Bank Charles Rhyee - TD Cowen Eric Percher - Nephron Research Steven Valiquette - Mizuho Securities Allen Lutz - Bank of America Daniel Grosslight - Citi Kevin Caliendo - UBS Erin Wright - Morgan Stanley Operator Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today.

Cencora, Inc. (COR) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™